Plasmodium RNA triphosphatase validation as antimalarial target Articles uri icon

authors

  • MOLINER CUBEL, SONIA
  • BAHAMONTES ROSA, NOEMÍ
  • RODRÍGUEZ ALEJANDRE, ANE
  • NASSAU, PAMELA M.
  • ARGYROU, ARGYRIDS
  • BHARDWAJA, ANSHU
  • BUXTON, RACHEL C.
  • CALVO VICENTE, DAVID
  • MOUZON, BERNADETTE
  • MCDOWELL, WILLIAM
  • MENDOZA LOSANA, ALFONSO
  • GÓMEZ LORENZO, MARÍA G.

publication date

  • May 2024

volume

  • 25

International Standard Serial Number (ISSN)

  • 2211-3207

abstract

  • Target-based approaches have traditionally been used in the search for new anti-infective molecules. Target selection process, a critical step in Drug Discovery, identifies targets that are essential to establish or maintain the infection, tractable to be susceptible for inhibition, selective towards their human ortholog and amenable for large scale purification and high throughput screening. The work presented herein validates the Plasmodium falciparum mRNA 5' triphosphatase (PfPRT1), the first enzymatic step to cap parasite nuclear mRNAs, as a candidate target for the development of new antimalarial compounds. mRNA capping is essential to maintain the integrity and stability of the messengers, allowing their translation. PfPRT1 has been identified as a member of the tunnel, metal dependent mRNA 5' triphosphatase family which differs structurally and mechanistically from human metal independent mRNA 5' triphosphatase. In the present study the essentiality of PfPRT1 was confirmed and molecular biology tools and methods for target purification, enzymatic assessment and target engagement were developed, with the goal of running a future high throughput screening to discover PfPRT1 inhibitors.

subjects

  • Biology and Biomedicine

keywords

  • mrna 5' triphosphatase; pfprt1; pvprt1; plasmodium falciparum; plasmodium vivax; malaria